Table 1

Baseline characteristics

SexAge at diagnosis (years)Hormonal functionStage at diagnosisSites of metastatic disease at initiation of LEN/PEMGenetic findings
1M37NoIVLungs, liver, bone PTEN and CDKN2B mutations
2F22NoIIILungNo mutations
3F21YesIILung, liver, adrenal bed TP53 mutation (germline)
4M39NoIVLiver, lung, retroperitoneum, and boneNo mutations
5M44YesIVLung CDK4, MDM2, and CCND3 mutations
6M34YesIILung, abdomen, and liver CTNNB1 and TP53 mutation (germline)
7F41NoIIILung, abdomen, pelvis, and liver CTNNB1, ATRX, MUTYH, and RB1 mutations
8F49NoIILung, abdomen, and liverNo mutations
  • LEN, lenvatinib; PEM, pembrolizumab.